SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/11/22 Achieve Life Sciences, Inc. 10-Q 6/30/22 60:7.3M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 2.15M 2: EX-31.1 Certification -- §302 - SOA'02 HTML 22K 3: EX-32.1 Certification -- §906 - SOA'02 HTML 20K 9: R1 Document and Entity Information HTML 75K 10: R2 Consolidated Balance Sheets (Unaudited) HTML 118K 11: R3 Consolidated Balance Sheets (Parenthetical) HTML 39K (Unaudited) 12: R4 Consolidated Statements of Loss and Comprehensive HTML 69K Loss (Unaudited) 13: R5 Consolidated Statements of Cash Flows (Unaudited) HTML 84K 14: R6 Consolidated Statements of Stockholder's Equity HTML 86K (Unaudited) 15: R7 Nature of Business, Basis of Presentation and HTML 28K Going Concern Uncertainty 16: R8 Accounting Policies HTML 23K 17: R9 Government Grant HTML 23K 18: R10 Intangibles HTML 62K 19: R11 License Agreements HTML 27K 20: R12 Fair Value Measurements HTML 132K 21: R13 Convertible Debt HTML 58K 22: R14 Common Stock HTML 207K 23: R15 Commitments and Contingencies HTML 128K 24: R16 Intangibles (Tables) HTML 62K 25: R17 Fair Value Measurements (Tables) HTML 149K 26: R18 Convertible Debt (Tables) HTML 70K 27: R19 Common Stock (Tables) HTML 186K 28: R20 Commitments and Contingencies (Tables) HTML 125K 29: R21 Nature of Business, Basis of Presentation and HTML 43K Going Concern Uncertainty - Additional Information (Detail) 30: R22 Government Grant - Additional Information HTML 31K (Details) 31: R23 Intangibles - Additional Information (Detail) HTML 29K 32: R24 Intangibles - Components of Intangible Assets HTML 28K (Detail) 33: R25 Intangibles - Estimated Future Amortization HTML 30K Expense Related to Intangible Assets (Detail) 34: R26 License Agreements - Additional Information HTML 27K (Detail) 35: R27 Fair Value Measurements - Additional Information HTML 24K (Detail) 36: R28 Fair Value Measurements - Summary of Assets HTML 30K Measured at Fair Value on Recurring Basis (Detail) 37: R29 Fair Value Measurements - Summary of Cash HTML 27K Equivalents (Detail) 38: R30 Fair Value Measurements - Schedule of Aggregate HTML 27K Fair Value of Principal Amount of Convertible Debt (Detail) 39: R31 Convertible Debt - Additional Information HTML 73K (Details) 40: R32 Convertible Debt - Schedule of Convertible Debt HTML 30K Balance (Details) 41: R33 Common Stock - Authorized - Additional Information HTML 27K (Detail) 42: R34 Common Stock - Issued and Outstanding Shares - HTML 57K Additional Information (Detail) 43: R35 Common Stock - Stock Options - Additional HTML 100K Information (Detail) 44: R36 Common Stock - Summary of Stock Options Activity HTML 34K (Detail) 45: R37 Common Stock - Summary of Fair Value of Each Stock HTML 29K Award for Employees and Directors (Detail) 46: R38 Common Stock - Summary of Share-Based Compensation HTML 27K Expense for Stock Options, Restricted Stock and Employee Share Purchase Plan (Detail) 47: R39 Common Stock - Restricted Stock Unit Awards - HTML 30K Additional Information (Detail) 48: R40 Common Stock - Summary of Restricted Stock Unit HTML 37K Award Activity (Detail) 49: R41 Common Stock - Employee Share Purchase Plan - HTML 24K Additional Information (Detail) 50: R42 Common Stock - Summary of Outstanding Warrants HTML 52K (Detail) 51: R43 Common Stock - Common Stock Warrants - Additional HTML 31K Information (Detail) 52: R44 Commitments and Contingencies - Summary of HTML 25K Contractual Obligations (Detail) 53: R45 Commitments and Contingencies - Additional HTML 68K Information (Detail) 54: R46 Commitments and Contingencies - Summary of Future HTML 26K Minimum Annual Lease Payments (Detail) 55: R47 Commitments and Contingencies - Summary of Other HTML 28K Information Related to Leases (Detail) 58: XML IDEA XML File -- Filing Summary XML 109K 56: XML XBRL Instance -- achv-10q_20220630_htm XML 1.57M 57: EXCEL IDEA Workbook of Financial Reports XLSX 98K 5: EX-101.CAL XBRL Calculations -- achv-20220630_cal XML 110K 6: EX-101.DEF XBRL Definitions -- achv-20220630_def XML 496K 7: EX-101.LAB XBRL Labels -- achv-20220630_lab XML 967K 8: EX-101.PRE XBRL Presentations -- achv-20220630_pre XML 710K 4: EX-101.SCH XBRL Schema -- achv-20220630 XSD 150K 59: JSON XBRL Instance as JSON Data -- MetaLinks 288± 461K 60: ZIP XBRL Zipped Folder -- 0001564590-22-029122-xbrl Zip 350K
Exhibit 31.1
Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934
I, John Bencich, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Achieve Life Sciences, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 11, 2022
|
|
/s/ John Bencich |
|
|
|
|
|
Chief Executive Officer (Principal Executive and Financial Officer) |
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 8/11/22 | 8-K | ||
For Period end: | 6/30/22 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/12/23 Achieve Life Sciences, Inc. 424B7 1:173K Donnelley … Solutions/FA 12/29/22 Achieve Life Sciences, Inc. S-3 4:276K Donnelley … Solutions/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/27/22 Achieve Life Sciences, Inc. 8-K:1,2,8,9 4/26/22 14:3.8M ActiveDisclosure/FA |